Patents by Inventor H. Craig Dees

H. Craig Dees has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020161035
    Abstract: New chemotherapeutic medicaments and certain medical uses and methods for use of such chemotherapeutic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal. The halogenated xanthenes constitute a family of useful chemotherapeutic agents that afford selective, persistent accumulation in certain tissues.
    Type: Application
    Filed: July 6, 2001
    Publication date: October 31, 2002
    Applicant: Photogen, Inc.
    Inventors: H. Craig Dees, Timothy C. Scott
  • Patent number: 6468777
    Abstract: A method for increasing production yield of viruses, viral proteins, and other related biological materials through enhanced control and stabilization of protein production via stress proteins and the resultant protein products. The present invention is also directed to methods for selection or engineering of cell lines yielding such enhanced stabilized products. More specifically, example embodiments of the present invention are directed to methods for enhancing production of a viral agent, production of cell lines exhibiting permanent genetic modification, production of permissive eucaryotic cell lines, enhancing functional recombinant product yield, and the products of such methods.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: October 22, 2002
    Assignee: Photogen, Inc.
    Inventors: H. Craig Dees, John Smolik
  • Patent number: 6451597
    Abstract: A method for increasing production yield of viruses, viral proteins, and other related biological materials through enhanced control and stabilization of protein production via stress proteins and the resultant protein products. The present invention is also directed to methods for selection or engineering of cell lines yielding such enhanced stabilized products. More specifically, example embodiments of the present invention are directed to methods for enhancing production of a viral agent, production of cell lines exhibiting permanent genetic modification, production of permissive eucaryotic cell lines, enhancing functional recombinant product yield, and the products of such methods.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: September 17, 2002
    Assignee: Photogen, Inc.
    Inventors: H. Craig Dees, John Smolik
  • Publication number: 20020107281
    Abstract: The present invention is directed to new methods, medicaments and pharmaceutical compositions and agents for improved cancer treatment that lower recurrence of the primary tumor by causing selective, acute destruction of tumor tissue and thereby exposing the immune system to large amounts of substantially non-denatured tumor material over a short period of time. This effectively vaccinates the host against tumor tissue, allowing the host's immune system to attack any residual tumor tissue, and thereby reduces the recurrence rate and metastasis to remote sites. In preferred embodiments, this enhancement is achieved through application of phototherapeutic or chemotherapeutic modalities that are capable of producing such an acute, necrotic effect on treated lesions without completely denaturing tumor antigens.
    Type: Application
    Filed: September 14, 2001
    Publication date: August 8, 2002
    Applicant: Photogen, Inc.
    Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter
  • Publication number: 20020001567
    Abstract: New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of potent radiosensitizers that become photoactivated upon irradiation of the treatment site with ionizing radiation.
    Type: Application
    Filed: March 26, 2001
    Publication date: January 3, 2002
    Applicant: Photogen, Inc.
    Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
  • Patent number: 6331286
    Abstract: Methods of treating and imaging diseased tissue having the steps of administering a radiosensitizer agent proximate to or into the diseased tissue; and treating the diseased tissue with x-rays or other ionizing radiation so as to activate the radiosensitizer agent in the diseased tissue. Preferably, the radiosensitizer agent is a halogenated xanthene.
    Type: Grant
    Filed: December 21, 1998
    Date of Patent: December 18, 2001
    Assignee: Photogen, Inc.
    Inventors: H. Craig Dees, Timothy Scott, John T. Smolik, Eric A. Wachter
  • Publication number: 20010044146
    Abstract: A method for increasing production yield of viruses, viral proteins, and other related biological materials through enhanced control and stabilization of protein production via stress proteins and the resultant protein products. The present invention is also directed to methods for selection or engineering of cell lines yielding such enhanced stabilized products. More specifically, example embodiments of the present invention are directed to methods for enhancing production of a viral agent, production of cell lines exhibiting permanent genetic modification, production of permissive eucaryotic cell lines, enhancing functional recombinant product yield, and the products of such methods.
    Type: Application
    Filed: March 9, 2001
    Publication date: November 22, 2001
    Applicant: Photogen, Inc.
    Inventors: H. Craig Dees, John Smolik
  • Publication number: 20010041361
    Abstract: A method for increasing production yield of viruses, viral proteins, and other related biological materials through enhanced control and stabilization of protein production via stress proteins and the resultant protein products. The present invention is also directed to methods for selection or engineering of cell lines yielding such enhanced stabilized products. More specifically, example embodiments of the present invention are directed to methods for enhancing production of a viral agent, production of cell lines exhibiting permanent genetic modification, production of permissive eucaryotic cell lines, enhancing functional recombinant product yield, and the products of such methods.
    Type: Application
    Filed: March 9, 2001
    Publication date: November 15, 2001
    Applicant: Photogen, Inc
    Inventors: H. Craig Dees, John Smolik
  • Publication number: 20010041354
    Abstract: A method for increasing production yield of viruses, viral proteins, and other related biological materials through enhanced control and stabilization of protein production via stress proteins and the resultant protein products. The present invention is also directed to methods for selection or engineering of cell lines yielding such enhanced stabilized products. More specifically, example embodiments of the present invention are directed to methods for enhancing production of a viral agent, production of cell lines exhibiting permanent genetic modification, production of permissive eucaryotic cell lines, enhancing functional recombinant product yield, and the products of such methods.
    Type: Application
    Filed: March 9, 2001
    Publication date: November 15, 2001
    Applicant: Photogen, Inc.
    Inventors: H. Craig Dees, John Smolik
  • Publication number: 20010022970
    Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.
    Type: Application
    Filed: March 6, 2001
    Publication date: September 20, 2001
    Applicant: Photogen, Inc.
    Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
  • Patent number: 6042603
    Abstract: An apparatus for the treatment of a particular volume of plant or animal tissue by treating the plant or animal tissue with at least one photo-active molecular agent, wherein the particular volume of the plant or animal tissue retains at least a portion of the at least one photo-active molecular agent, and then treating the particular volume of the plant or animal tissue with light sufficient to promote a simultaneous two-photon excitation of at least one of the at least one photo-active molecular agent retained in the particular volume of the plant or animal tissue, wherein the at least one photo-active molecular agent becomes active in the particular volume of the plant or animal tissue.
    Type: Grant
    Filed: May 4, 1998
    Date of Patent: March 28, 2000
    Assignee: Photogen, Inc.
    Inventors: Walter G. Fisher, Eric A. Wachter, H. Craig Dees
  • Patent number: 5998597
    Abstract: A method for the treatment of a particular volume of plant or animal tissue comprising the steps of treating the plant or animal tissue with at least one photo-active molecular agent, wherein the particular volume of the plant or animal tissue retains at least a portion of the at least one photo-active molecular agent, and then treating the particular volume of the plant or animal tissue with light sufficient to promote a simultaneous two-photon excitation of at least one of the at least one photo-active molecular agent retained in the particular volume of the plant or animal tissue, wherein the at least one photo-active molecular agent becomes active in the particular volume of the plant or animal tissue. There is also disclosed a method for the treatment of cancer in plant or animal tissue and a method for producing at least one photo-activated molecular agent in a particular volume of a material.
    Type: Grant
    Filed: December 11, 1997
    Date of Patent: December 7, 1999
    Assignee: Photogen, Inc.
    Inventors: Walter G. Fisher, Eric A. Wachter, H. Craig Dees
  • Patent number: 5958740
    Abstract: An enhanced strain of Pseudomonas celllulosa was obtained by introducing a recombinant genetic construct comprising a heterologous cellulase gene operably connected to a promoter into ATCC 55702, mutagenizing the transformants by treatment with MNNG, and selecting a high cellulase producing transformant. The transformant, designated Pseudomonas cellulosa ATCC XXXX, exhibits enhanced levels of cellulase production relative to the untransformed Pseudomonas cellulosa strain #142 ATCC 55702.
    Type: Grant
    Filed: September 22, 1997
    Date of Patent: September 28, 1999
    Assignee: Lockheed Martin Energy Research Corp.
    Inventor: H. Craig Dees
  • Patent number: 5832931
    Abstract: A method for the imaging of a particular volume of plant or animal tissue, wherein the plant or animal tissue contains at least one photo-active molecular agent. The method includes the steps of treating the particular volume of the plant or animal tissue with light sufficient to promote a simultaneous two-photon excitation of the photo-active molecular agent contained in the particular volume of the plant or animal tissue, photo-activating at least one of the at least one photo-active molecular agent in the particular volume of the plant or animal tissue, thereby producing at least one photo-activated molecular agent, wherein the at least one photo-activated molecular agent emits energy, detecting the energy emitted by the at least one photo-activated molecular agent, and producing a detected energy signal which is characteristic of the particular volume of plant or animal tissue.
    Type: Grant
    Filed: October 30, 1996
    Date of Patent: November 10, 1998
    Assignee: Photogen, Inc.
    Inventors: Eric A. Wachter, Walter G. Fisher, H. Craig Dees
  • Patent number: 5829448
    Abstract: A method for the treatment of a particular volume of plant or animal tissue comprising the steps of treating the plant or animal tissue with at least one photo-active molecular agent, wherein the particular volume of the plant or animal tissue retains at least a portion of the at least one photo-active molecular agent, and then treating the particular volume of the plant or animal tissue with light sufficient to promote a simultaneous two-photon excitation of at least one of the at least one photo-active molecular agent retained in the particular volume of the plant or animal tissue, wherein the at least one photo-active molecular agent becomes active in the particular volume of the plant or animal tissue. There is also disclosed a method for the treatment of cancer in plant or animal tissue and a method for producing at least one photo-activated molecular agent in a particular volume of a material.
    Type: Grant
    Filed: October 30, 1996
    Date of Patent: November 3, 1998
    Assignee: Photogen, Inc.
    Inventors: Walter G. Fisher, Eric A. Wachter, H. Craig Dees
  • Patent number: 5789227
    Abstract: Bacteria which produce large amounts of a cellulase-containing cell-free fermentate, have been identified. The original bacterium (ATCC 55703) was genetically altered using nitrosoguanidine (MNNG) treatment to produce the enhanced cellulase degrading bacterium ATCC 55702, which was identified through replicate plating. ATCC 55702 has improved characteristics and qualities for the degradation of cellulosic materials.
    Type: Grant
    Filed: September 14, 1995
    Date of Patent: August 4, 1998
    Assignee: Lockheed Martin Energy Systems, Inc.
    Inventor: H. Craig Dees
  • Patent number: 5780422
    Abstract: Bacteria which produce large amounts of a cellulase-containing cell-free fermentate have been identified. The original bacterium (ATCC 55703) was genetically altered using nitrosoguanidine (MNNG) treatment to produce the enhanced cellulase producing bacterium (ATCC 55702), which was identified through replicate plating. ATCC 55702 has improved characteristics and qualities for the degradation of cellulosic waste materials for fuel production, food processing, textile processing, and other industrial applications. ATCC 55702 is an improved bacterial host for genetic manipulations using recombinant DNA techniques, and is less likely to destroy genetic manipulations using standard mutagenesis techniques.
    Type: Grant
    Filed: October 8, 1996
    Date of Patent: July 14, 1998
    Assignee: Lockheed Martin Energy Systems, Inc.
    Inventor: H. Craig Dees
  • Patent number: 5756337
    Abstract: Bacteria which produce large amounts of cellulose-containing cell-free fermentate have been identified. The original bacterium (ATCC 55703) was genetically altered using nitrosoguanidine (MNNG) treatment to produce the enhanced cellulase producing bacterium (ATCC 55702), which was identified through replicate plating. ATCC 55702 has improved characteristics and qualities for the degradation of cellulosic waste materials for fuel production, food processing, textile processing, and other industrial applications. ATCC 55702 is an improved bacterial host for genetic manipulations using recombinant DNA techniques, and is less likely to destroy genetic manipulations using standard mutagenesis techniques.
    Type: Grant
    Filed: October 8, 1996
    Date of Patent: May 26, 1998
    Assignee: Lockheed Martin Energy Systems, Inc.
    Inventor: H. Craig Dees
  • Patent number: 5702940
    Abstract: Bacteria which produce large amounts of cellulase--containing cell-free fermentate have been identified. The original bacterium (ATCC 55703) was genetically altered using nitrosoguanidine (MNNG) treatment to produce the enhanced cellulase producing bacterium (ATCC 55702), which was identified through replicate plating. ATCC 55702 has improved characteristics and qualifies for the degradation of cellulosic waste materials for fuel production, food processing, textile processing, and other industrial applications. ATCC 55702 is an improved bacterial host for genetic manipulations using recombinant DNA techniques, and is less likely to destroy genetic manipulations using standard mutagenesis techniques.
    Type: Grant
    Filed: October 8, 1996
    Date of Patent: December 30, 1997
    Assignee: Lockheed Martin Energy Systems, Inc.
    Inventor: H. Craig Dees
  • Patent number: 5698429
    Abstract: Bacteria which produce large amounts of cellulase-containing cell-free fermentate have been identified. The original bacterium (ATCC 55703) was genetically altered using nitrosoguanidine (MNNG) treatment to produce the enhanced cellulase producing bacterium (ATCC 55702), which was identified through replicate plating. ATCC 55702 has improved characteristics and qualities for the degradation of cellulosic waste materials for fuel production, food processing, textile processing, and other industrial applications. ATCC 55702 is an improved bacterial host for genetic manipulations using recombinant DNA techniques, and is less likely to destroy genetic manipulations using standard mutagenesis techniques.
    Type: Grant
    Filed: October 8, 1996
    Date of Patent: December 16, 1997
    Assignee: Lockheed Martin Energy Systems, Inc.
    Inventor: H. Craig Dees